Vaxart Gets Increased Funding for COVID-19 Pill Vaccine Study

MT Newswires Live2024-12-28

Vaxart (VXRT) said an agreement with Advanced Technology International on a COVID-19 vaccine candidate study was amended with an increase of $4.6 million in the total estimated ceiling for funding to $460.7 million.

The project agreement in June covered funding for a comparative study to evaluate the company's oral pill XBB COVID-19 vaccine candidate against an mRNA vaccine comparator approved by the US Food and Drug Administration, Vaxart said Friday in a regulatory filing.

The amendment boosted the funding allotted to the phase 2b trial by $37.7 million to $134.2 million available for payment, Vaxart said.

Advanced Technology International is a consortium management firm funded by the US Department of Health and Human Services' Biomedical Advanced Research and

Development Authority.

Price: 0.66, Change: +0.05, Percent Change: +8.59

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2494387956?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-28 00:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2494387956","market":"sh","top_or_hot":-1,"title":"Vaxart Gets Increased Funding for COVID-19 Pill Vaccine Study","media":"MT Newswires Live","content":"<html><body><p> Vaxart (VXRT) said an agreement with Advanced Technology International on a COVID-19 vaccine candidate study was amended with an increase of $4.6 million in the total estimated ceiling for funding to $460.7 million.</p><p>The project agreement in June covered funding for a comparative study to evaluate the company's oral pill XBB COVID-19 vaccine candidate against an mRNA vaccine comparator approved by the US Food and Drug Administration, Vaxart said Friday in a regulatory filing.</p><p>The amendment boosted the funding allotted to the phase 2b trial by $37.7 million to $134.2 million available for payment, Vaxart said.</p><p>Advanced Technology International is a consortium management firm funded by the US Department of Health and Human Services' Biomedical Advanced Research and</p><p>Development Authority.</p><p>Price: 0.66, Change: +0.05, Percent Change: +8.59</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart Gets Increased Funding for COVID-19 Pill Vaccine Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart Gets Increased Funding for COVID-19 Pill Vaccine Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-28 00:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaxart (VXRT) said an agreement with Advanced Technology International on a COVID-19 vaccine candidate study was amended with an increase of $4.6 million in the total estimated ceiling for funding to ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2494387956","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2494387956","pubTimestamp":1735316402,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Vaxart  said an agreement with Advanced Technology International on a COVID-19 vaccine candidate study was amended with an increase of $4.6 million in the total estimated ceiling for funding to $460.7 million.The project agreement in June covered funding for a comparative study to evaluate the company's oral pill XBB COVID-19 vaccine candidate against an mRNA vaccine comparator approved by the US Food and Drug Administration, Vaxart said Friday in a regulatory filing.The amendment boosted the funding allotted to the phase 2b trial by $37.7 million to $134.2 million available for payment, Vaxart said.Advanced Technology International is a consortium management firm funded by the US Department of Health and Human Services' Biomedical Advanced Research andDevelopment Authority.Price: 0.66, Change: +0.05, Percent Change: +8.59","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Vaxart为COVID-19药丸疫苗研究获得更多资金","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":1,"VXRT":0.9},"content_text":"Vaxart (VXRT) said an agreement with Advanced Technology International on a COVID-19 vaccine candidate study was amended with an increase of $4.6 million in the total estimated ceiling for funding to $460.7 million.The project agreement in June covered funding for a comparative study to evaluate the company's oral pill XBB COVID-19 vaccine candidate against an mRNA vaccine comparator approved by the US Food and Drug Administration, Vaxart said Friday in a regulatory filing.The amendment boosted the funding allotted to the phase 2b trial by $37.7 million to $134.2 million available for payment, Vaxart said.Advanced Technology International is a consortium management firm funded by the US Department of Health and Human Services' Biomedical Advanced Research andDevelopment Authority.Price: 0.66, Change: +0.05, Percent Change: +8.59","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2494387956"}